An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
The intranasal vaccine contributed to multifaceted immune responses, leading to robust cross protection against influenza in mice. The vaccine consists of PEI-HA/CpG nanoparticles. PEI (polyethyleneimine), a robust and versatile delivery system, can simultaneously carry antigens (hemagglutinin, HA) that induce an immune response in the body, and adjuvants (CpG) that enhance the body’s immune response to an antigen for optimal immunoenhancement.
These comprehensive immune responses and cross protection were long lasting, exhibiting defense from influenza virus over six months after immunization. The findings are published in the journal ACS Applied Materials & Interfaces.
Intranasal vaccination is an ideal approach for infectious respiratory diseases such as influenza. Seasonal influenza vaccines generally induce narrow immune responses that rapidly decline, which leaves populations vulnerable to novel influenza strains. Advancements in influenza vaccine technology are needed to protect against a wide range of influenza viruses. Intranasal vaccination can improve local mucosal immune responses by preventing influenza infection at the portal of virus entry.
In the influenza virus, HA is a protein that plays a crucial role in the early stages of virus infection. Influenza HA has a head region and stalk region. Current influenza vaccines elicit immune responses against the HA head, but this head region is highly changeable and accounts for lowered efficiency against different strains. The HA stalk region is more conservative across different strains of influenza viruses.
Protein antigens that are administered intranasally are usually less able to provoke an immune response, so adjuvants are needed to have highly efficient intranasal vaccines. Adjuvants, such as CpG, can enhance and manipulate immune responses, thus improving the potency and breadth of protection.
“The PEI-HA/CpG nanoparticles show good potential as a cross-protective influenza vaccine candidate,” said Dr. Baozhong Wang, corresponding author of the study and a professor in the Institute for Biomedical Sciences at Georgia State. “The combination of PEI and CpG in the PEI-HA/CpG nanoparticle group contributed to the multifaceted immune responses, leading to vigorous cross protection. The incorporation of CpG and antigens into the same nanoparticle enhanced cellular immune responses.
“Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, or the ability to provoke an immune response, providing cross protection against different influenza virus strains. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups.”
“Nanoparticle platforms have shown intriguing characteristics and great potentials in the development of next-generation cross-protective influenza vaccines,” said Dr. Chunhong Dong, the first author of the study and a postdoctoral fellow in the Institute for Biomedical Sciences. “However, challenges exist to the successful research and development of nanoparticle vaccines. Though no apparent adverse effects were observed in the study, a more comprehensive safety evaluation of the nanoparticle adjuvant system is needed before clinical trials.”
Original Article: Intranasal Flu Vaccine with Nanoparticles Offers Robust Protection, Researchers Find
More from: Georgia State University
The Latest on: Nanoparticle influenza vaccine
- Influenza cases: Maha reports 318 H3N2 and 432 H1N1 cases in 2023on March 27, 2023 at 12:16 pm
A release by the Maharashtra government on Thursday showed that the state reported 3,36,518 suspected influenza cases in 2023 (From January 1 to March 26). Among them, 1851 suspected flu patients were ...
- The Evolving History of Influenza Viruses and Influenza Vaccineson March 25, 2023 at 5:00 pm
The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was ...
- The Evolving History of Influenza Viruses and Influenza Vaccineson March 23, 2023 at 5:00 pm
The first research programs attempting to develop an inactivated influenza vaccine, outside of the USSR, were conducted in England and in the USA at about the same time. However, it was at the ...
- An mRNA Influenza Vaccine — Could It Deliver?on March 23, 2023 at 2:04 am
The development of a universal influenza vaccine that confers broad and durable ... and enhance translation and then is encapsulated within a lipid nanoparticle (LNP). The rapid scalability ...
- Flu fighter: Nanoparticle-based vaccine effective in preclinical trialson March 21, 2023 at 5:01 pm
BUFFALO, N.Y. — An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body has proven effective in preclinical studies.
- How Much Revenue Does the “Influenza Vaccine Market” Generate?on March 7, 2023 at 7:01 pm
Mar 07, 2023 (The Expresswire) -- The "Influenza Vaccine Market" analysis [UPDATED REPORT] 2023 provides an assessment of a specific industry, niche, or vertical which helps you know your target ...
- Beyond COVID vaccines: what’s next for lipid nanoparticles?on February 14, 2023 at 9:44 pm
Lipid nanoparticles (LNPs) transport small molecules into the body. The most well-known LNP cargo is mRNA, the key constituent of some of the early vaccines against COVID-19. But that is just one ...
- Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccineon April 28, 2022 at 11:36 am
The safety and tolerability profile of the combination vaccine was consistent with the stand-alone NVX-CoV2373 and quadrivalent nanoparticle influenza vaccine reference formulations in the trial.
- Collaborative Research and Licensing Opportunity: Novel Multivalent Nanoparticle Vaccineson September 4, 2020 at 12:06 pm
Current seasonal influenza vaccines are designed to elicit immunity ... recombinant fusion proteins that self-assemble into nanoparticles with influenza antigenic proteins displayed on the ...
- Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccineon August 18, 2020 at 10:32 pm
2 We recently described an adjuvanted recombinant hemagglutinin (HA) trivalent nanoparticle influenza vaccine (tNIV), produced on an Sf9 insect cell–recombinant baculovirus platform made from ...
via Bing News
The Latest on: Nanoparticle influenza vaccine
[google_news title=”” keyword=”nanoparticle influenza vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News